GlassScriptPhysician profile
Jason Elia Mastor
NPI 1598857401
$18,912.90
in general payments reported to CMS, 2019-2025
38 companies · $4,965 in 2025
The $4,965 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,548 · 2020: $1,521 · 2021: $1,550 · 2022: $2,281 · 2023: $3,622 · 2024: $3,426 · 2025: $4,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $990 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,996.19 |
| Travel and Lodging | $989.84 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,218.39 | 2019-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $2,022.71 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $1,938.46 | 2019-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,276.82 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,234.98 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,208.21 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $980.00 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $933.85 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $811.42 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $677.32 | 2022-2025 | Auvelity, Sunosi |
| Neos Therapeutics, LP | $661.19 | 2019-2025 | Adzenys Xr-Odt, Exxua |
| Supernus Pharmaceuticals, INC. | $577.50 | 2022-2025 | Qelbree, Qelbree |
| Almatica Pharma LLC | $520.76 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $430.85 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $378.47 | 2019-2023 | Belsomra |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $368.50 | 2019-2020 | |
| Alkermes, INC. | $352.31 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $342.03 | 2022-2025 | Fanapt |
| Avanir Pharmaceuticals, INC. | $330.32 | 2019-2022 | |
| Allergan, INC. | $315.79 | 2019-2020 | |
| Tris Pharma INC | $226.96 | 2022-2025 | Dyanavel Xr |
| Eisai INC. | $185.65 | 2020-2022 | |
| Noven Therapeutics, LLC | $174.01 | 2023-2025 | Xelstrym, Secuado |
| Corium, LLC | $134.28 | 2022-2023 | Azstarys, Adlarity |
| Shire North American Group INC | $79.57 | 2019 | |
| Adlon Therapeutics L.P. | $77.59 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $76.69 | 2019 | |
| Livanova USA, INC. | $65.94 | 2023-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Neuronetics, INC. | $51.31 | 2019 | |
| Novo Nordisk INC | $50.96 | 2019-2024 | |
| Acadia Pharmaceuticals INC | $50.80 | 2021-2025 | Nuplazid |
| Vertical Pharmaceuticals, LLC | $35.40 | 2019 | |
| Harmony Biosciences LLC | $30.63 | 2023 | Wakix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $27.50 | 2025 | Rejoyn |
| Owp Pharmaceuticals, INC. | $22.48 | 2022 | |
| Lilly USA, LLC | $15.12 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.02 | 2019 | |
| Bausch Health US, LLC | $13.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Mastor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.